Trial Profile
A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Diagnostic use
- Acronyms BoneMetPETCT
- 12 Aug 2022 Status changed from active, no longer recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 30 Nov 2021 to 31 Mar 2023.
- 02 Aug 2021 Planned End Date changed from 1 Nov 2021 to 30 Nov 2021.